Mirabegron Patent Expiration
Mirabegron is used for treating neurogenic detrusor overactivity in pediatric patients and overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, including in combination with solifenacin succinate for more severe cases. It was first introduced by Astellas Pharma Global Development Inc
Mirabegron Patents
Given below is the list of patents protecting Mirabegron, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Myrbetriq Granules |
US10058536 (Pediatric) | Pharmaceutical composition containing mirabegron | Sep 30, 2036 | Apgdi |
| Myrbetriq Granules | US10058536 | Pharmaceutical composition containing mirabegron | Mar 31, 2036 | Apgdi |
| Myrbetriq |
US10842780 (Pediatric) | Pharmaceutical composition for modified release | Mar 28, 2030 | Apgdi |
| Myrbetriq |
US11707451 (Pediatric) | Pharmaceutical composition for modified release | Mar 28, 2030 | Apgdi |
| Myrbetriq |
US12059409 (Pediatric) | Pharmaceutical composition for modified release | Mar 28, 2030 | Apgdi |
| Myrbetriq |
US12097189 (Pediatric) | Pharmaceutical composition for modified release | Mar 28, 2030 | Apgdi |
| Myrbetriq | US10842780 | Pharmaceutical composition for modified release | Sep 28, 2029 | Apgdi |
| Myrbetriq | US11707451 | Pharmaceutical composition for modified release | Sep 28, 2029 | Apgdi |
| Myrbetriq | US12059409 | Pharmaceutical composition for modified release | Sep 28, 2029 | Apgdi |
| Myrbetriq | US12097189 | Pharmaceutical composition for modified release | Sep 28, 2029 | Apgdi |
| Myrbetriq |
US8772315 (Pediatric) | Pharmaceutical composition for treating overactive bladder | Apr 30, 2029 | Apgdi |
| Myrbetriq | US8772315 | Pharmaceutical composition for treating overactive bladder | Oct 30, 2028 | Apgdi |
| Myrbetriq |
US7342117 (Pediatric) | α-form or β-form crystal of acetanilide derivative |
May 04, 2024
(Expired) | Apgdi |
| Myrbetriq |
US7982049 (Pediatric) | α-form or β-form crystal of acetanilide derivative |
May 04, 2024
(Expired) | Apgdi |
| Myrbetriq |
US8835474 (Pediatric) | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May 04, 2024
(Expired) | Apgdi |
| Myrbetriq |
USRE44872 (Pediatric) | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May 04, 2024
(Expired) | Apgdi |
| Myrbetriq Granules |
US7342117 (Pediatric) | α-form or β-form crystal of acetanilide derivative |
May 04, 2024
(Expired) | Apgdi |
| Myrbetriq Granules |
US7982049 (Pediatric) | α-form or β-form crystal of acetanilide derivative |
May 04, 2024
(Expired) | Apgdi |
| Myrbetriq | US7750029 | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Dec 18, 2023
(Expired) | Apgdi |
| Myrbetriq | US7342117 | α-form or β-form crystal of acetanilide derivative |
Nov 04, 2023
(Expired) | Apgdi |
| Myrbetriq | US7982049 | α-form or β-form crystal of acetanilide derivative |
Nov 04, 2023
(Expired) | Apgdi |
| Myrbetriq | US8835474 | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov 04, 2023
(Expired) | Apgdi |
| Myrbetriq | USRE44872 | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov 04, 2023
(Expired) | Apgdi |
| Myrbetriq Granules | US7342117 | α-form or β-form crystal of acetanilide derivative |
Nov 04, 2023
(Expired) | Apgdi |
| Myrbetriq Granules | US7982049 | α-form or β-form crystal of acetanilide derivative |
Nov 04, 2023
(Expired) | Apgdi |
| Myrbetriq |
US6346532 (Pediatric) | Amide derivatives or salts thereof |
Sep 27, 2022
(Expired) | Apgdi |
| Myrbetriq Granules |
US6346532 (Pediatric) | Amide derivatives or salts thereof |
Sep 27, 2022
(Expired) | Apgdi |
| Myrbetriq Granules | US6346532 | Amide derivatives or salts thereof |
Mar 27, 2022
(Expired) | Apgdi |
| Myrbetriq | US6562375 | Stable pharmaceutical composition for oral use |
Aug 01, 2020
(Expired) | Apgdi |
| Myrbetriq | US6346532 | Amide derivatives or salts thereof |
Oct 15, 2018
(Expired) | Apgdi |
| Myrbetriq | US6699503 | Hydrogel-forming sustained-release preparation |
Sep 10, 2013
(Expired) | Apgdi |
Mirabegron's Family Patents
